Trulicity — Revenue
Products & Services · RevenueEli Lilly Trulicity — Revenue decreased by 1.4% to $1.04B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 17.1%, from $1.25B to $1.04B. Over 4 years (FY 2021 to FY 2025), Trulicity — Revenue shows a downward trend with a -9.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful patient retention for the product, while a decrease may signal market share erosion due to competition from newer therapies or changes in payer coverage.
Detailed definition
This metric represents the total net sales generated by the Trulicity product line, a glucagon-like peptide-1 (GLP-1) re...
Peer comparison
Comparable to revenue metrics for specific blockbuster drug franchises or key therapeutic product lines at other large-cap pharmaceutical companies.
lly_segment_trulicity_member_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.54B | $1.60B | $1.88B | $1.74B | $1.91B | $1.85B | $1.94B | $1.98B | $1.81B | $1.67B | $1.67B | $1.46B | $1.25B | $1.30B | $1.25B | $1.10B | $1.09B | $1.05B | $1.04B |
| QoQ Change | — | +4.2% | +17.7% | -7.6% | +9.8% | -3.2% | +4.6% | +2.1% | -8.3% | -7.7% | -0.3% | -12.8% | -14.5% | +4.5% | -3.9% | -12.4% | -0.3% | -3.7% | -1.4% |
| YoY Change | — | — | — | — | +24.5% | +15.6% | +2.8% | +13.5% | -5.2% | -9.6% | -13.8% | -26.3% | -31.3% | -22.2% | -25.1% | -24.8% | -12.3% | -19.2% | -17.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's trulicity — revenue?
- Eli Lilly (LLY) reported trulicity — revenue of $1.04B in Q4 2025.
- How has Eli Lilly's trulicity — revenue changed year-over-year?
- Eli Lilly's trulicity — revenue decreased by 17.1% year-over-year, from $1.25B to $1.04B.
- What is the long-term trend for Eli Lilly's trulicity — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's trulicity — revenue has grown at a -9.8% compound annual growth rate (CAGR), from $6.47B to $4.28B.
- What does trulicity — revenue mean?
- The total revenue generated from sales of the Trulicity diabetes medication.